​Merck should follow GSK’s lead and commit to selling its potential Ebola vaccine at cost

Between disease names that few people have ever heard of and scientific jargon, it’s rare for the results of a drug trial to make for an easily understandable headline. That was not the case this morning when Reuters reported a story headline, “ Merck’s Ebola vaccine proves fully effective in Guinea trial.” Everyone knows Ebola. That’s the disease in Africa that’s killed more than 11,000 people since December 2013, and made some people freak out last fall because President Barack Obama…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news